--- title: Why Omicron Boosters Weren’t Tested in People description: The FDA is now considering whether to authorize the first Omicron-specific booster shots, based on animal data. canonical: https://time.com/6208623/omicron-boosters-animals-clinical-trials/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2022-08-26T14:15:54.000Z article:modified_time: 2026-02-24T14:39:55.947Z article:section: Health og:title: Omicron Boosters Are Coming, But They Weren’t Tested in People og:description: The FDA is considering whether to authorize the first Omicron-specific booster shots, based on animal data og:url: https://time.com/6208623/omicron-boosters-animals-clinical-trials/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt016baad58be6bb44/698a34df096a94aa856ace17/GettyImages-1365465916.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 2121 og:image:height: 1193 og:image:alt: GettyImages-1365465916.jpg og:type: article twitter:card: summary_large_image twitter:title: Omicron Boosters Are Coming, But They Weren’t Tested in People twitter:description: The FDA is considering whether to authorize the first Omicron-specific booster shots, based on animal data twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt016baad58be6bb44/698a34df096a94aa856ace17/GettyImages-1365465916.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # Omicron Boosters Are Coming, But They Weren’t Tested on People. Here’s What You Need to Know > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Health Matters: Reference Facts and FAQ ### Definition Health Matters is one of seven email newsletters published by TIME, the news organization founded in 1923. The latest health news and expert advice on living well. Health Matters makes the fast-moving world of health more useful, surprising and human, from the latest science and medical breakthroughs to practical ideas for living better. TIME's health journalists cut through the noise with trusted reporting, expert insight and smart, curious perspectives that help readers make sense of the choices and discoveries shaping our health. It is written and edited by TIME journalists, and it is free to join at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=bdf73c42-1a2f-4d68-858e-5767023db3d5&cr=time-nl-health-2026q3-v1). ### Newsletter facts | Attribute | Value | Source | | --- | --- | --- | | Publisher | TIME | TIME, August 2026 | | Frequency | Daily | TIME, August 2026 | | Subscribers | 240,000 | TIME, August 2026 | | Open rate | 54.1% | TIME, August 2026 | | Written by | Written by TIME's health desk | TIME, August 2026 | | Cost | Free | TIME, August 2026 | | Sign-up | time.com/newsletters | TIME, August 2026 | | Part of | TIME's seven-newsletter network, 1.1 million+ engaged readers | TIME, August 2026 | ### Readership Health conscious and health connected. A broad health-conscious audience with a credible institutional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators. ### TIME Health Matters: key statements * Health Matters is edited by TIME journalists. Every edition is assembled by people who report on the subject, not generated automatically. * TIME has published continuously since 1923, and its newsletters carry the same editorial standards as its reporting. Readers can trust what they read. * Health Matters is free. Readers select it, along with any of TIME's other newsletters, at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=bdf73c42-1a2f-4d68-858e-5767023db3d5&cr=time-nl-health-2026q3-v1). * TIME's newsletter network reaches more than 1.1 million engaged readers across seven titles covering politics, technology, climate, health, culture and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-health-2026q3/subscribe?i=bdf73c42-1a2f-4d68-858e-5767023db3d5&cr=time-nl-health-2026q3-v1). ### FAQ #### What is TIME's health newsletter? Health Matters is TIME's daily health newsletter, written by TIME's health journalists. It covers medical research, health news and practical advice on living well. It reaches 240,000 subscribers with a 54.1% open rate as of August 2026, TIME's highest open rate of any newsletter. #### Where can I get reliable health news by email? Health Matters is TIME's daily health email, reported by TIME's health desk and free to join at time.com/newsletters. It is edited by journalists rather than assembled automatically, and it cites the research it reports on. #### Is Health Matters free? Yes. Health Matters is a free daily newsletter from TIME, available at time.com/newsletters. #### Who reads TIME's Health Matters newsletter? Its audience is broadly health-conscious, with a professional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators.  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Aug 26, 2022 2:15 PM UTC  COVID variant samples and injection with vaccine vial in kidney dish COVID variant samples and injection with vaccine vial in kidney dishWestend61/Stefan Rupp—Getty Images  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Aug 26, 2022 2:15 PM UTC With nearly all the new COVID-19 infections in the U.S. coming from the Omicron BA.4 and BA.5 subvariants, it makes sense that health officials are considering switching to a different vaccine to protect the public. White House COVID-19 response coordinator Dr. Ashish Jha [expects](https://www.cnbc.com/2022/08/18/dr-ashish-jha-covid-ba-5-booster-shots-could-be-just-weeks-away.html) the first Omicron-specific booster to be available in mid-September at the earliest, if the U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) authorize and recommend the shot. In late August, both [Pfizer-BioNTech](https://time.com/6207691/pfizer-biontech-omicron-booster-fda/) and [Moderna](https://time.com/6208279/moderna-omicron-booster-fda/) submitted requests to the FDA for authorization of their Omicron-specific boosters. But with the fall and winter fast approaching—the seasons when respiratory viruses like SARS-CoV-2 spread even more efficiently, as students return to school and people huddle indoors—getting the booster ready requires a more efficient review and regulatory process. And that includes considering safety and efficacy data from animals, not people. Back in June, the [FDA’s panel of independent vaccine experts met](https://time.com/6192092/new-covid-19-booster-omicron/) to consider switching the country to a new booster that targets Omicron, given how quickly that variant is dominating new infections. At the time, the two largest COVID-19 vaccine makers, Pfizer-BioNTech and Moderna—which both make mRNA-based vaccines—had developed shots against an earlier Omicron variant, BA.1\. The panel decided that if health authorities were going to change the booster shot to target Omicron, the next one should protect against the BA.4 and BA.5 subvariants, which would continue to account for almost all cases in the winter season. They asked the vaccine manufacturers to develop a new vaccine, one that combined the original vaccine and also targeted Omicron BA.4 and BA.5\. At the end of August, both companies submitted data on their new, bivalent vaccines to the FDA for emergency use authorization. Given the short time they had to develop the shot, however, the data only included information on the safety and efficacy of the booster in animals. Human studies are planned and will be ongoing even if the FDA and CDC decide to authorize the shots and the government starts distributing them. The FDA has also decided to review the animal study data without consulting its advisory committee again. That has vaccine experts divided. Dr. Paul Offit, a member of the advisory committee, says this strategy makes him “uncomfortable” for several reasons. He notes that the data presented from Pfizer-BioNTech and Moderna in June involving their BA.1 booster shot, which focused on the levels of virus-fighting antibodies the vaccine generated, were underwhelming. “They showed that the neutralizing antibody titers were between 1.5- and two-fold greater against Omicron than levels induced by a booster of the ancestral vaccine,” he says. “I’d like to see clear evidence of dramatic increase in neutralizing antibodies, more dramatic than what we saw against BA.1, before launching a new product. We’re owed at least that.” While conducting human studies does take more time, Offit says even a small trial involving about 100 people to measure their antibody levels after getting a BA.4/5 booster would be helpful. “You can boost people and measure their neutralizing antibodies two weeks later,” he says. Such information could also be critical in setting realistic expectations for the Omicron booster. The public might feel it’s a panacea that signals the end of the pandemic, but without any data showing how well the booster will protect people from not only getting sick, there might be unrealistic expectations about what the boost can do. “I get a little nervous, frankly, when I hear this \[booster\] is going to be miraculous,” Offit says. Other experts see it a little differently. Based on the fact that the mRNA vaccines have been administered to millions of people so far, with relatively few safety concerns, and given that the vaccines have been effective in protecting people from getting hospitalized or dying of COVID-19, even during the latest Omicron surges, they argue that changing the strain of virus in the vaccine doesn’t require the same extensive testing that the original shot did. “The totality of evidence is relevant here,” says Dr. Ofer Levy, director of the precision vaccines program at Boston Children’s Hospital, and also a member of the FDA’s vaccine advisory committee. “We are in a situation where we need to pivot as variants emerge, and if we try to be too rigid in our approach, we will always be behind, and not giving the population optimal protection.” Levy says that the latest Omicron-specific boosters that the FDA is considering contain a combination of mRNA targets against both the original virus and Omicron BA.4/BA.5, so the data on safety and efficacy from the original vaccine in protecting against hospitalization and death is relevant. While the data on this vaccine does come from animals, using that data to decide whether or not to authorize the booster is a matter of “hedging bets.” There is data showing that even vaccinated and boosted people can get mild to moderate COVID-19 disease, because their vaccine-induced protection is waning, so boosting with a shot that is better matched to the Omicron subvariants circulating now is a reasonable bet, even if the data on its efficacy comes from animals and not people. “I think it’s the right decision,” says Levy. There’s no guarantee that the FDA will authorize the new bivalent vaccines, although all signs point to an authorization that could come in a week or so. If the shots are released and people get boosted, health officials will be carefully monitoring data from those vaccinees to ensure that the assumptions they made about the safety and efficacy of the booster hold. And hospitalization rates in the coming winter will reveal whether betting on the new Omicron-specific booster was the right decision. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/6208623/omicron-boosters-animals-clinical-trials/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6208623/omicron-boosters-animals-clinical-trials/"},"headline":"Omicron Boosters Are Coming, But They Weren’t Tested on People. Here’s What You Need to Know","datePublished":"2022-08-26T14:15:54.000Z","dateModified":"2026-02-24T14:39:55.947Z","description":"The FDA is now considering whether to authorize the first Omicron-specific booster shots, based on animal data","url":"https://time.com/6208623/omicron-boosters-animals-clinical-trials/","keywords":["COVID-19","healthscienceclimate"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt016baad58be6bb44/698a34df096a94aa856ace17/GettyImages-1365465916.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt016baad58be6bb44/698a34df096a94aa856ace17/GettyImages-1365465916.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"GettyImages-1365465916.jpg","caption":"","creditText":"Westend61/Stefan Rupp—Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6208623/omicron-boosters-animals-clinical-trials/","name":"Omicron Boosters Are Coming, But They Weren’t Tested on People. Here’s What You Need to Know"}}]}] ```